Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

BACKGROUND: Cancer immunotherapy is under development as a promising alternative strategy for treating advanced non‐small cell lung cancer (NSCLC). However, the development of novel biomarkers to optimize the use of immune checkpoint inhibitors (ICIs) is still ongoing. Gut microbiota are known to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Katayama, Yuki, Yamada, Tadaaki, Tanimura, Keiko, Yoshimura, Akihiro, Takeda, Takayuki, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397896/
https://www.ncbi.nlm.nih.gov/pubmed/30666802
http://dx.doi.org/10.1111/1759-7714.12969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397896/
https://www.ncbi.nlm.nih.gov/pubmed/30666802
http://dx.doi.org/10.1111/1759-7714.12969

Ejemplares similares